TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE

Post-LOE

trandolapril and verapamil hydrochloride

Ichnos Glenmark Innovation

ANDAORALTABLET, EXTENDED RELEASE

Approved

May 2010

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE (trandolapril and verapamil hydrochloride) by Ichnos Glenmark Innovation is angiotensin-converting enzyme inhibitors [moa]. Approved for hypertension. First approved in 2010.

Drug data last refreshed 23h ago

Mechanism of Action

Angiotensin-converting Enzyme Inhibitors

Pharmacologic Class:

Angiotensin Converting Enzyme Inhibitor

Indications (1)

hypertension

Company

Worked on TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE at Ichnos Glenmark Innovation? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.